- Home
- OKYO vs RPTX Comparison
OKYO vs RPTX Comparison
Compare OKYO & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- RPTX
- Stock Information
- Founded
- OKYO 2007
- RPTX 2016
- Country
- OKYO United Kingdom
- RPTX Canada
- Employees
- OKYO N/A
- RPTX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- RPTX Health Care
- Exchange
- OKYO Nasdaq
- RPTX Nasdaq
- Market Cap
- OKYO 37.0M
- RPTX 58.8M
- IPO Year
- OKYO 2022
- RPTX 2020
- Fundamental
- Price
- OKYO $1.85
- RPTX $1.37
- Analyst Decision
- OKYO Strong Buy
- RPTX Strong Buy
- Analyst Count
- OKYO 1
- RPTX 3
- Target Price
- OKYO $7.00
- RPTX $4.50
- AVG Volume (30 Days)
- OKYO 198.3K
- RPTX 190.7K
- Earning Date
- OKYO 06-06-2025
- RPTX 05-13-2025
- Dividend Yield
- OKYO N/A
- RPTX N/A
- EPS Growth
- OKYO N/A
- RPTX N/A
- EPS
- OKYO N/A
- RPTX N/A
- Revenue
- OKYO N/A
- RPTX $1,073,000.00
- Revenue This Year
- OKYO N/A
- RPTX N/A
- Revenue Next Year
- OKYO N/A
- RPTX N/A
- P/E Ratio
- OKYO N/A
- RPTX N/A
- Revenue Growth
- OKYO N/A
- RPTX N/A
- 52 Week Low
- OKYO $0.81
- RPTX $0.89
- 52 Week High
- OKYO $1.98
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- OKYO 62.66
- RPTX 55.96
- Support Level
- OKYO $1.70
- RPTX $1.33
- Resistance Level
- OKYO $1.98
- RPTX $1.41
- Average True Range (ATR)
- OKYO 0.18
- RPTX 0.07
- MACD
- OKYO 0.03
- RPTX -0.01
- Stochastic Oscillator
- OKYO 80.30
- RPTX 55.56
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.